TCM
TSHA icon

TCG Crossover Management’s Taysha Gene Therapies TSHA Stock Holding History

TCG Crossover Management’s Portfolio TSHA Stock Details TSHA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-2,912,861
Closed -$5.16M – 35
2023
Q4 		$5.16M Sell
2,912,861
-8,198,250
-74% -$16.3M 0.57% 27
2023
Q3 		$35.1M Buy
+11,111,111
New +$20.8M 5.17% 6

Other funds holding TSHA

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
VA
VR Adviser New York $3.3B AUM 525.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
TCM
Tybourne Capital Management Hong Kong $30.9M AUM 20.1% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return

TCG Crossover Management's TSHA Position: Q1 2024 in Review

TCG Crossover Management sold out of Taysha Gene Therapies (TSHA) in Q1 2024, closing a stake of 2,912,861 shares — an estimated $5.16M sold.

TCG Crossover Management first reported a position in TSHA in Q3 2023 and held it in 2 quarters. The position peaked at $35.1M in Q3 2023. 109 funds tracked by Wall St. Rank hold TSHA as of Q1 2024.

  • TCG Crossover Management reported no remaining Taysha Gene Therapies position as of Q1 2024 after selling out during the quarter.
  • TCG Crossover Management sold 2,912,861 Taysha Gene Therapies shares in Q1 2024, an estimated $5.16M.
  • TCG Crossover Management first reported a position in Taysha Gene Therapies in Q3 2023 and held it in 2 quarters.
  • TCG Crossover Management's Taysha Gene Therapies position peaked at $35.1M in Q3 2023.
  • 109 funds tracked by Wall St. Rank held Taysha Gene Therapies as of Q1 2024.

Based on TCG Crossover Management's 13F filing for Q1 2024, filed 15 May 2024.